CY1120875T1 - Ν-(ετερο)αρυλ-υποκατασταθεντα ετεροκυκλικα παραγωγα χρησιμα για την αγωγη νοσων ή παθησεων που σχετιζονται με το κεντρικο νευρικο συστημα - Google Patents

Ν-(ετερο)αρυλ-υποκατασταθεντα ετεροκυκλικα παραγωγα χρησιμα για την αγωγη νοσων ή παθησεων που σχετιζονται με το κεντρικο νευρικο συστημα

Info

Publication number
CY1120875T1
CY1120875T1 CY181100879T CY181100879T CY1120875T1 CY 1120875 T1 CY1120875 T1 CY 1120875T1 CY 181100879 T CY181100879 T CY 181100879T CY 181100879 T CY181100879 T CY 181100879T CY 1120875 T1 CY1120875 T1 CY 1120875T1
Authority
CY
Cyprus
Prior art keywords
diseases
treatment
aryl
nervous system
central nervous
Prior art date
Application number
CY181100879T
Other languages
English (en)
Inventor
Susanna Cremonesi
Fabrizio Micheli
Teresa Semeraro
Luca Tarsi
Tim Luker
Colin Leslie
Original Assignee
Chronos Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chronos Therapeutics Ltd filed Critical Chronos Therapeutics Ltd
Publication of CY1120875T1 publication Critical patent/CY1120875T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις τύπου (I), συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις, τη χρήση αυτών των ενώσεων στη θεραπεία (για παράδειγμα, στην αγωγή ή πρόληψη μίας νόσου, διαταραχής ή παθήσεως που βελτιώνεται μέσω αναστολής ενός μεταφορέα ντοπαμίνης) και μεθόδους αγωγής ασθενών με αυτές τις ενώσεις· όπου τα R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L και Β είναι όπως ορίζεται στο παρόν.
CY181100879T 2014-09-16 2018-08-23 Ν-(ετερο)αρυλ-υποκατασταθεντα ετεροκυκλικα παραγωγα χρησιμα για την αγωγη νοσων ή παθησεων που σχετιζονται με το κεντρικο νευρικο συστημα CY1120875T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1416351.3A GB201416351D0 (en) 2014-09-16 2014-09-16 Heterocyclic derivatives
PCT/IB2015/057031 WO2016042453A1 (en) 2014-09-16 2015-09-14 N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system

Publications (1)

Publication Number Publication Date
CY1120875T1 true CY1120875T1 (el) 2019-12-11

Family

ID=51869694

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100879T CY1120875T1 (el) 2014-09-16 2018-08-23 Ν-(ετερο)αρυλ-υποκατασταθεντα ετεροκυκλικα παραγωγα χρησιμα για την αγωγη νοσων ή παθησεων που σχετιζονται με το κεντρικο νευρικο συστημα

Country Status (19)

Country Link
US (1) US9920053B2 (el)
EP (1) EP3194385B3 (el)
JP (3) JP6800855B2 (el)
CN (2) CN111848577B (el)
AU (1) AU2015316472C1 (el)
BR (1) BR112017005241B1 (el)
CA (1) CA2997869C (el)
CY (1) CY1120875T1 (el)
DK (1) DK3194385T6 (el)
ES (1) ES2687604T7 (el)
GB (1) GB201416351D0 (el)
HR (1) HRP20181391T1 (el)
HU (1) HUE040647T2 (el)
LT (1) LT3194385T (el)
PL (1) PL3194385T6 (el)
PT (1) PT3194385T (el)
RS (1) RS57617B1 (el)
SI (1) SI3194385T1 (el)
WO (1) WO2016042453A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201416351D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6835371B1 (en) 1997-09-12 2004-12-28 David R. Elmaleh Diagnostic and therapeutic piperazine and piperidine compounds and process
PL355540A1 (en) * 1999-12-30 2004-05-04 H.Lundbeck A/S Phenylpiperazinyl derivatives
IL154575A0 (en) * 2000-08-30 2003-09-17 Hoffmann La Roche Selective cyclic peptides
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US6956042B2 (en) 2002-07-05 2005-10-18 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
EP1683797A1 (en) 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
CA2575461A1 (en) 2004-08-20 2006-03-02 Targacept, Inc. The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
RU2396257C2 (ru) * 2004-12-20 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные 4-аминопиперидина
CN101228127B (zh) * 2005-05-30 2012-05-16 Msdk.K.公司 哌啶衍生物
CA2626496A1 (en) 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors
GB0522715D0 (en) * 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
AU2006333522A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
US7728031B2 (en) * 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
WO2007148185A2 (en) * 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
CA2656089A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
US8148408B2 (en) * 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
WO2012024397A2 (en) 2010-08-17 2012-02-23 Albany Molecular Research, Inc. 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9884865B2 (en) 2013-08-26 2018-02-06 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
WO2015107494A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
ES2666173T3 (es) 2014-03-17 2018-05-03 Remynd Nv Compuestos de 2,7-diazaespiro[3.5]nonano
GB201416351D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives

Also Published As

Publication number Publication date
HUE040647T2 (hu) 2019-03-28
SI3194385T1 (sl) 2019-01-31
DK3194385T6 (da) 2021-05-17
JP6800855B2 (ja) 2020-12-16
JP2023012506A (ja) 2023-01-25
ES2687604T3 (es) 2018-10-26
PL3194385T6 (pl) 2021-06-14
WO2016042453A1 (en) 2016-03-24
BR112017005241B1 (pt) 2023-12-19
CN111848577B (zh) 2023-09-01
US20170253592A1 (en) 2017-09-07
GB201416351D0 (en) 2014-10-29
PT3194385T (pt) 2018-10-19
CA2997869A1 (en) 2016-03-24
RS57617B1 (sr) 2018-11-30
AU2015316472B2 (en) 2020-04-09
JP2017527632A (ja) 2017-09-21
CN107001318B (zh) 2020-08-11
CA2997869C (en) 2023-03-07
PL3194385T3 (pl) 2018-11-30
HRP20181391T1 (hr) 2018-10-19
JP2021042231A (ja) 2021-03-18
EP3194385A1 (en) 2017-07-26
CN111848577A (zh) 2020-10-30
AU2015316472C1 (en) 2020-10-29
AU2015316472A1 (en) 2017-04-20
LT3194385T (lt) 2018-09-25
EP3194385B3 (en) 2021-02-17
NZ730702A (en) 2023-09-29
ES2687604T7 (es) 2021-11-17
US9920053B2 (en) 2018-03-20
EP3194385B1 (en) 2018-06-20
CN107001318A (zh) 2017-08-01
BR112017005241A2 (pt) 2017-12-19
DK3194385T3 (en) 2018-10-01

Similar Documents

Publication Publication Date Title
CY1121030T1 (el) Προφαρμακα πυριδονο αμιδιων χρησιμα ως διαμορφωτες διαυλων νατριου
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1123961T1 (el) Ανοσορυθμιστικοι παραγοντες
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1123246T1 (el) Συνθεσεις και μεθοδοι για τη θεραπευτικη αντιμετωπιση διαταραχων του κνς
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1124113T1 (el) Συνθεσεις και μεθοδοι για την θεραπευτικη αντιμετωπιση διαταραχων κνς
CY1124022T1 (el) Σχημα χορηγησης για νιτροκατεχολες
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
CY1117200T1 (el) Παραγωγα βενζυλαμινης ως αναστολεις καλλικρεϊνης πλασματος
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
CY1120490T1 (el) Φαρμακο για την προληψη και/ή την θεραπευτικη αντιμετωπιση της πολυκυστικης νοσου των νεφρων
CU20170007A7 (es) Compuestos de imidazopiridazina
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
EA201491854A1 (ru) Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1120836T1 (el) Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CY1120573T1 (el) Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов